Certain statements contained in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including without limitation statements regarding the merger and the ability to consummate the merger. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Ra Pharma undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) Ra Pharma may be unable to obtain shareholder approval as required for the merger; (2) conditions to the closing of the merger may not be satisfied and required regulatory approvals may not be obtained; (3) the merger may involve unexpected costs, liabilities or delays; (4) Ra Pharma's business may suffer as a result of uncertainty surrounding the merger; (5) the outcome of any legal proceedings that may arise related to the merger; (6) Ra Pharma may be adversely affected by other economic, business, and/or competitive factors; (7) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; and (8) the ability to recognize benefits of the merger; (9) risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; and (10) other risks to consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. If the merger is consummated, Ra Pharma shareholders will cease to have any equity interest in Ra Pharma and will have no right to participate in its earnings and future growth. Additional factors that may affect the future results of Ra Pharma are set forth in its filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2018, which is available on the SEC's website at www.sec.gov [http://www.sec.gov/]. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.
CONTACT: For further information - UCB - Corporate Communications, FranceNivelle, Global Communications, UCB, T: +32-2-559-9178,france.nivelle@ucb.com; Laurent Schots, Media Relations, UCB, T:+32-2-559-92-64, Laurent.schots@ucb.com; UCB - Investor Relations: AntjeWitte, Investor Relations, UCB, T: +32-2-559-94-14, antje.witte@ucb.com;Isabelle Ghellynck, Investor Relations, UCB, T: +32-2-559-9588,isabelle.ghellynck@ucb.com; Ra Pharmaceuticals, Inc.: Investors: RaPharmaceuticals, Inc., Natalie Wildenradt, 617-674-9874,nwildenradt@rapharma.com; Media: Argot Partners, David Rosen, 212-600-1902david.rosen@argotpartners.com; Allyson Funk, Head of U.S. Communicationsand Public Affairs, 770-970-8338, allyson.funk@ucb.com
Web site: http://www.ucb.com/http://www.RaPharma.c...
